Minretumomab

Source: Wikipedia, the free encyclopedia.
Minretumomab
radiolabelled)
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Minretumomab (CC49) is a

Phase I clinical trials for this purpose.[4]

Derivatives

A wide range of derivatives has been used in pharmaceutical research. Examples include chimeric[5] and humanized minretumomab,[6] as well as a fusion protein of a minretumomab single-chain variable fragment and the enzyme beta-lactamase.[7]

Radiopharmaceuticals

Iodine (125I) minretumomab is an

CA 72-4.[8]

Radiolabelled minretumomab has also been tested for the treatment of solid tumours, but without success. Iodine (

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 13 (3). 1999.
  2. ^ "TAG-72 antigen". NCI Dictionary of Cancer Terms. National Cancer Institute. 2011-02-02.
  3. S2CID 205469234
    .
  4. ^ "Studies found for: CC49". ClinicalTrials.gov.
  5. ^ .
  6. .
  7. .
  8. .